

10/577746

LAP17 Rec'd PCT/PTO 27 APR 2006

[Kind of Document]

Specification

[Title of the Invention]

TRANSDERMAL PREPARATIONS AND
METHOD FOR RELIEVING SIDE EFFECTS IN PERGOLIDE THERAPY

[Claim]

[Claim 1] A transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof, wherein said preparation is capable of achieving a plasma AUC ratio of pergolide or the pharmaceutically acceptable salt thereof to at least one metabolite thereof of 1:0.5 to 1:5.

[Claim 2] The transdermal preparation according to claim 1, wherein the plasma AUC ratio of pergolide and/or a pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:3.5.

[Claim 3] The transdermal preparation according to claim 2, wherein the plasma AUC ratio of pergolide and/or a pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:2.

[Claim 4] The transdermal preparation according to any one of claims 1 to 3, wherein the metabolite is one or more kinds comprising pergolide sulfoxide, pergolide sulfone, despropyl pergolide or despropyl pergolide sulfoxide.

[Claim 5] The transdermal preparation according to claim 4, wherein the metabolite is pergolide sulfoxide.

[Claim 6] The transdermal preparation according to any one of claims 1 to 5, wherein the pharmaceutically acceptable salt is one or more kinds comprising hydrochloride, sulfate, mesylate, citrate,

fumarate, tartarate, maleate or acetate.

[Claim 7] The transdermal preparation according to claim 6, wherein the pharmaceutically acceptable salt is mesylate.

[Claim 8] The transdermal preparation according to any one of claims 1 to 7, wherein the ratio (A/B) of the maximum plasma level (A) of pergolide and/or the pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration and/or the ratio (A'/B') of the maximum plasma level (A') of pergolide sulfoxide to the plasma level (B') of pergolide sulfoxide in the next administration is less than 2.

[Claim 9] The transdermal preparation according to any one of claims 1 to 8, wherein (meth)acrylic acid copolymer is contained in an adhesive layer.

[Claim 10] The transdermal preparation according to claim 9, wherein the acrylic polymer except (meth)acrylic acid copolymer is further contained in an adhesive layer.

[Claim 11] A transdermal preparation containing pergolide and/or the pharmaceutically acceptable salt thereof, wherein the ratio (A/B) of the maximum plasma level (A) of pergolide and/or the pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration and/or the ratio (A'/B') of the maximum plasma level (A') of pergolide sulfoxide to the plasma level (B') of pergolide sulfoxide in the next administration is less than 2.

[Claim 12] The transdermal preparation according to any one of claims 1 to 11, wherein said preparation is an adhesive patch.